A Delphi Study of Core Patient-Reported Outcomes for Advanced Renal Cell Carcinoma and Advanced Hepatocellular Carcinoma

被引:1
|
作者
de la Serna, Celia Diez de los Rios [1 ]
Drury, Amanda [2 ]
Oldenmenger, Wendy H. [3 ]
Kelly, Daniel [4 ]
Kotronoulas, Grigorios [5 ]
机构
[1] European Oncol Nursing Soc EONS, Oncol Adv Nurse Practitioner, Brussels, Belgium
[2] Dublin City Univ, Sch Nursing Psychotherapy & Community Hlth, Dublin, Ireland
[3] Univ Med Ctr, Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands
[4] Cardiff Univ, Sch Healthcare Sci, Cardiff, Wales
[5] Univ Glasgow, Sch Med Dent & Nursing, Glasgow City, Scotland
关键词
Patient-reported outcomes; Advanced renal cell carcinoma; Cancer; Advanced hepatocellular carcinoma; Quality of life; Person-centered care; QUALITY-OF-LIFE; CANCER; PROS; CARE;
D O I
10.1016/j.soncn.2023.151409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: There is little research to help health care professionals understand what patient outcomes are considered a priority in advanced liver or kidney cancer. Knowing what is important to patients can help pro-mote person-centered approaches to treatment and disease management. The aim of this study was to identify those patient-reported outcomes (PROs) that patients, carers, and health care professionals consider as "core" when providing care to those with advanced liver or kidney cancer.Data sources: A three-round Delphi study was undertaken to ask experts by profession or experience to rank PROs identified from a previous literature review. Fifty-four experts, including people living with advanced liver or kidney cancer (44.4%), family members and caregivers (9.3%), and health care professionals (46.8%), reached consensus on 49 PROs including 12 new items (eg, palpitations, hopefulness, or social isolation). Items with the highest rate of consensus included quality of life, pain, mental health, and capacity to do daily activities.Conclusion: People living with advanced liver or kidney cancer experience complex health care needs. Some important outcomes were not actually captured in practice in this population and were suggested as part of this study. There are discrepancies between the views of health care professionals, patients, and family in what is important, highlighting the need of using measures to facilitate communication. Implications for Nursing Practice: Identification of priority PROs reported here will be key to facilitate more focused patient assessments. The actual use of measures in cancer nursing practice to allow monitoring of PROs must be tested for feasibility and usability.& COPY; 2023 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
引用
收藏
页数:8
相关论文
共 50 条
  • [1] A rapid review of patient-reported outcomes investigated in the context of advanced renal cell cancer or advanced hepatocellular cancer
    de la Serna, Celia Diez de los Rios
    Kotronoulas, Grigorios
    Drury, Amanda
    Oldenmenger, Wendy
    Kelly, Daniel
    EUROPEAN JOURNAL OF ONCOLOGY NURSING, 2023, 63
  • [2] Patient-reported Outcome Measurement and Reporting for Patients with Advanced Renal Cell Carcinoma: A Systematic Literature Review
    Motzer, Robert J.
    Rane, Pratik P.
    Saretsky, Todd L.
    Pawar, Deepshikha
    Nguyen, Allison Martin
    Sundaram, Murali
    Burgents, Joseph
    Pandey, Rishabh
    Rudell, Katja
    EUROPEAN UROLOGY, 2023, 84 (04) : 406 - 417
  • [3] Are we ready for patient-reported outcomes in hepatocellular carcinoma? Comment
    Personeni, Nicola
    Rimassa, Lorenza
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (08): : 602 - 603
  • [4] Patient-reported outcomes in liver transplant recipients with hepatocellular carcinoma
    Kensinger, Clark D.
    Feurer, Irene D.
    O'Dell, Heather W.
    LaNeve, David C.
    Simmons, Lindsey
    Pinson, C. Wright
    Moore, Derek E.
    CLINICAL TRANSPLANTATION, 2016, 30 (09) : 1036 - 1045
  • [5] Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
    Yalcin, Suayib
    Lacin, Sahin
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 7779 - 7785
  • [6] Outcomes and prognosis in advanced renal cell carcinoma
    Galsky, Matthew D.
    Vogelzang, Nicholas J.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2007, 7 (06) : 839 - 845
  • [7] Optimizing Outcomes in Advanced Renal Cell Carcinoma
    Adly, Sarah
    Caliendo, Tina
    US PHARMACIST, 2024, 49 (06)
  • [8] Patient-reported outcomes in elderly vs. young patients with advanced renal cell carcinoma treated with sorafenib vs. placebo
    Shah, S.
    Cella, D.
    Gondek, K.
    Cihon, F.
    Anderson, S.
    VALUE IN HEALTH, 2008, 11 (03) : A79 - A79
  • [9] Association between Patient-Reported Outcomes and Survival in Patients with Advanced Urothelial Carcinoma Treated with Atezolizumab
    Tan, Eugene
    Abuhelwa, Ahmad Y.
    Badaoui, Sarah
    Modi, Natansh D.
    Wiese, Michael D.
    McKinnon, Ross A.
    Sorich, Michael J.
    Hopkins, Ashley M.
    BLADDER CANCER, 2022, 8 (01) : 81 - 88
  • [10] Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study
    Hong, Sung-Hoo
    Chung, Ho Seok
    Seo, Ill-Young
    Kwon, Tae Gyun
    Jeong, Hyeon
    Chung, Jae-Il
    Jeon, Seung Hyun
    Park, Jae Young
    Ha, Hong Koo
    Chung, Byung-Ha
    Song, Wan
    Kim, Young-Joo
    Kim, Sang-Hee
    Lee, Jee-Sun
    Lee, Juneyoung
    Chung, Jinsoo
    JOURNAL OF PATIENT-REPORTED OUTCOMES, 2022, 6 (01)